FDA rejects Takeda/Shire candidate

Another clinical trial of TAK-721 is needed, says the US Food and Drug Administration, which has rejected the drug.
by mikkel aabenhus hemmingsen, translated by catherine brett

A new potential treatment for eosinophilic esophagitis (EoE), chronic inflammation of the esophagus, has been shot down by the FDA.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading